Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > World ADC 2024

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Oct 19, 2024 5:57pm

112 Views

Post# 36273366

RE:RE:World ADC 2024

One can be cautiously optimistic not only because of the language used but the fact that CMO published recently an article posted earlier here and attending various conferences, getting interviewed..

Lee430 wrote: Scarlet, reading between the lines of this quote you highlighted would one dare to infer that the trial is going well?

"We are still working to optimize the dose, but the trial program has provided us with some very important information about the unique MOA, the efficacy and improved safety profile, which is very different from that of its payload and from other ADCs already approved for use.”

scarlet1967 wrote:
https://web.hansonwadegroup.com/rs/355-DOS-429/images/World_ADC_San_Diego_2024_Speaker_Interview_Theratechnologies.pdf?utm_source=digital&utm_medium=social-post&utm_campaign=content&utm_content=linkedin/speaker-interview-hw-post/ev-41002

As per potentials for PDCs he mentioned dual payloads attached to peptides and radioligands having less bystander effects(less damage to healthy cells).

Also..

"We are still working to optimize the dose, but the trial program has provided us with some very important information about the unique MOA, the efficacy and improved safety profile, which is very different from that of its payload and from other ADCs already approved for use. This may enable combinations with other anti-cancer agents, such as targeted agents, CPls, and other PDCs/ADCs."